Giuseppe Barone 医生

Barone, G., Tweddle, D.A., Shohet, J.M., Chesler, L., Moreno, L., Pearson, A.D., Van Maerken, T., 2014.  MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Current Drug Targets. 15 (1) pp. 114-123.

Barone, G., Anderson, J., Pearson, A.D.K., Chesler, L., 2013. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res. 19 (21) pp. 5814-5821.

Riccardi, R*., Barone, G*., 2009. Severe infections in immunodepressed children. Minerva Pediatrica. 61 (6) pp. 854-856. (* joint first Authors)

Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, Moreno L, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma.Br J Cancer. 2016 Oct 25;115(9):1048-1057

Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson AD, Moreno L. Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. J Pediatr Hematol Oncol 2014, 36 (3), 218-223.

Moreno, L., Barone, G., Park, J. R., & Pearson, A. D. (2013). About the benefits of immunotherapy for high-risk neuroblastoma. J Clin Oncol, 31(5), 649-650. doi:10.1200/JCO.2012.47.4080

Moreno, L., Caron, H., Geoerger, B., Eggert, A., Schleiermacher, G., Brock, P., . . . Pearson, A. D. (2017). Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opin Drug Discov, 12(8), 801-811. doi:10.1080/17460441.2017.1340269

Di Francesco, A. M., Meco, D., Torella, A. R., Barone, G., D'Incalci, M., Pisano, C., . . . Riccardi, R. (2007). The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism. Biochemical pharmacology, 73(5), 643-655. doi:10.1016/j.bcp.2006.10.033

Di Francesco, A. M., Riccardi, A., Barone, G., Rutella, S., Meco, D., Frapolli, R., . . . Riccardi, R. (2005). The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. Biochemical pharmacology, 70(8), 1125-1136. doi:10.1016/j.bcp.2005.07.009

Di Francesco, A. M., Ubezio, P., Torella, A. R., Meco, D., Pierri, F., Barone, G., . . . Riccardi, R. (2012). Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical models. Invest New Drugs, 30(4), 1319-1330. doi:10.1007/s10637-011-9689-2

Moreno, L., Barone, G., Park, J. R., & Pearson, A. D. (2013). About the benefits of immunotherapy for high-risk neuroblastoma. J Clin Oncol, 31(5), 649-650. doi:10.1200/JCO.2012.47.4080

Moreno, L., Caron, H., Geoerger, B., Eggert, A., Schleiermacher, G., Brock, P., . . . Pearson, A. D. (2017). Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opin Drug Discov, 12(8), 801-811. doi:10.1080/17460441.2017.1340269

Morgenstern, D. A., Hargrave, D., Marshall, L. V., Gatz, S. A., Barone, G., Crowe, T., . . . Moreno, L. (2014). Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. J Pediatr Hematol Oncol, 36(3), 218-223. doi:10.1097/MPH.0000000000000003